Cardiomegaly

"Cardiomegaly" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Descriptor ID	D006332
MeSH Number(s)	C14.280.195 C23.300.775.250
Concept/Terms	Cardiomegaly Cardiomegaly Heart Enlargement Enlargement, Heart Enlarged Heart Heart, Enlarged Cardiac Hypertrophy Cardiac Hypertrophy Heart Hypertrophy

Below are MeSH descriptors whose meaning is more general than "Cardiomegaly".

Diseases [C]
Cardiovascular Diseases [C14]
Heart Diseases [C14.280]
Cardiomegaly [C14.280.195]
Pathological Conditions, Signs and Symptoms [C23]
Pathological Conditions, Anatomical [C23.300]
Hypertrophy [C23.300.775]
Cardiomegaly [C23.300.775.250]

Below are MeSH descriptors whose meaning is more specific than "Cardiomegaly".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cardiomegaly" by people in this website by year, and whether "Cardiomegaly" was a major or minor topic of these publications.

Bar chart showing 43 publications over 16 distinct years, with a maximum of 5 publications in 2009 and 2010 and 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	1	2
2002	1	0	1
2003	2	0	2
2004	1	0	1
2006	1	2	3
2007	0	2	2
2009	3	2	5
2010	2	3	5
2012	1	3	4
2014	4	1	5
2015	3	0	3
2016	2	1	3
2017	3	0	3
2019	2	0	2
2023	0	1	1
2024	0	1	1

Below are the most recent publications written about "Cardiomegaly" by people in Profiles.

Liu X, Li H, Hastings MH, Xiao C, Damilano F, Platt C, Lerchenm?ller C, Zhu H, Wei XP, Yeri A, Most P, Rosenzweig A. miR-222 inhibits pathological cardiac hypertrophy and heart failure. Cardiovasc Res. 2024 03 14; 120(3):262-272.

View in: PubMed
Pavri BB. Helping the hypertrophied (but nonobstructed) heart. Heart Rhythm. 2023 09; 20(9):1314-1315.

View in: PubMed
Kindermann W, Urhausen A, Scharhag J. Comment on: "Athlete's Heart: Diagnostic Challenges and Future Perspectives". Sports Med. 2019 03; 49(3):493-494.

View in: PubMed
Kindermann W, Urhausen A, Scharhag J. Comment on: Athlete's Heart: Is the Morganroth Hypothesis Obsolete? Heart Lung Circ. 2019 02; 28(2):e12-e13.

View in: PubMed
Schlegel P, Reinkober J, Meinhardt E, Tscheschner H, Gao E, Schumacher SM, Yuan A, Backs J, Most P, Wieland T, Koch WJ, Katus HA, Raake PW. G protein-coupled receptor kinase 2 promotes cardiac hypertrophy. PLoS One. 2017; 12(7):e0182110.

View in: PubMed
Higgins EM, Bos JM, Mason-Suares H, Tester DJ, Ackerman JP, MacRae CA, Sol-Church K, Gripp KW, Urrutia R, Ackerman MJ. Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy. JCI Insight. 2017 03 09; 2(5):e91225.

View in: PubMed
Abuzaid AS, Hamid SA, Gakhal M, Weiss S, Horn R, Weintraub W. Not All Chest Pains Are Made Equal: A Case of Apica Hypertrophic Cardiomyopathy. Del Med J. 2017 Feb; 89(2):54-56.

View in: PubMed
Beetz N, Rommel C, Schnick T, Neumann E, Lother A, Monroy-Ordonez EB, Zeeb M, Preissl S, Gilsbach R, Melchior-Becker A, Rylski B, Stoll M, Schaefer L, Beyersdorf F, Stiller B, Hein L. Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload. J Mol Cell Cardiol. 2016 Dec; 101:145-155.

View in: PubMed
Omede A, Zi M, Prehar S, Maqsood A, Stafford N, Mamas M, Cartwright E, Oceandy D. The oxoglutarate receptor 1 (OXGR1) modulates pressure overload-induced cardiac hypertrophy in mice. Biochem Biophys Res Commun. 2016 Oct 28; 479(4):708-714.

View in: PubMed
Khan SA, Dong H, Joyce J, Sasaki T, Chu ML, Tsuda T. Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)-?. Lab Invest. 2016 07; 96(7):773-83.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement